Iterum Therapeutics plc (ITRM)
Iterum Therapeutics plc
Fitzwilliam Court
1st Floor Leeson Close
Dublin D02 YW24
Ireland
353 1 669 4820
https://www.iterumtx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 14
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Corey N. Fishman | President, CEO & Director | 1.3M | N/D | 1965 |
| Ms. Judith M. Matthews | Chief Financial Officer | 747.77k | N/D | 1970 |
| Dr. Michael W. Dunne M.D. | Strategic Advisor & Director | 115k | N/D | 1960 |
| Dr. Sailaja Puttagunta M.D. | Chief Medical Officer | 946.83k | N/D | 1969 |
| Mr. Tom Loughman Ph.D. | Senior Vice President of Technical Operations | N/D | N/D | N/D |
| Ms. Louise Barrett | Senior Vice President of Legal Affairs & Secretary | N/D | N/D | N/D |
| Dr. Steven I. Aronin M.D. | Senior VP & Head of Clinical Development | N/D | N/D | N/D |
Descripción
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Gestión corporativa
La calificación ISS Governance QuickScore de Iterum Therapeutics plc a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
